AstraZeneca PLC

What they do

AstraZeneca develops, manufactures, and commercializes prescription medicines across several therapeutic areas, including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Diseases (via its Alexion subsidiary). It also has a Vaccines & Immune Therapies unit. Revenue is generated primarily from the sale of these products globally, with the US being the largest market.

Revenue drivers

• Oncology — Largest therapeutic area, driven by key products like Tagrisso, Imfinzi, Lynparza, and Calquence, contributing a substantial portion of total revenue.
• Cardiovascular, Renal & Metabolism (CVRM) — Major growth driver anchored by Farxiga, which continues to expand indications, supported by Brilinta and Lokelma.
• Rare Disease (Alexion) — Contributions from Ultomiris and Soliris, with growth from new rare disease products like Strensiq and Saphnelo.
• Respiratory & Immunology — Driven by Fasenra, Symbicort, and newer launches like Breztri and Airsupra, along with Tezspire and Beyfortus in vaccines/immune therapies.

Recent performance

For the fiscal year 2025 (ended December 31, 2025), AstraZeneca reported total revenue of $48.039 billion. The US market generated the largest share, with specific product revenues such as Farxiga, Tagrisso, Imfinzi, and Ultomiris being key contributors. The company reported increases across most therapeutic areas, with Oncology and Rare Disease showing particularly strong growth. Operating metrics reflected continued investment in R&D and commercial expansion.

Strategy

AstraZeneca's strategy focuses on driving growth through its core therapeutic areas, investing heavily in R&D to expand indications and develop new medicines. The company is leveraging its Alexion acquisition to build a leading rare disease portfolio and is expanding its presence in emerging markets. Management emphasizes innovation, with a robust pipeline and strategic collaborations, while also pursuing operational efficiencies and shareholder returns through dividends.

Risks

• Patent Expirations — Loss of exclusivity for key products like Tagrisso, Farxiga, and Imfinzi could lead to significant revenue decline from generic/biosimilar competition.
• Regulatory and Pricing Pressure — US drug pricing reforms (e.g., Inflation Reduction Act) and international pricing controls could reduce margins and profitability.
• Pipeline Failure — Late-stage clinical trial failures for key pipeline assets could setback growth projections and impair R&D investments.
• Manufacturing and Supply Chain Risks — Disruptions to complex supply chains or manufacturing quality issues could affect product availability and regulatory compliance.

Outlook

Management expects continued growth in 2026 and beyond, driven by product launches, label expansions, and geographic expansion. They anticipate strong performance in Oncology, CVRM, and Rare Disease, with margin improvement over time. However, they also acknowledge headwinds from patent expirations (e.g., Symbicort, Calquence) and regulatory changes. The company is guiding for core earnings growth and remains committed to returning capital through dividends.